8-K: LAVA Therapeutics Amends XOMA Royalty Acquisition Deal

LAVA Therapeutics and XOMA Royalty amend their acquisition agreement, reducing the cash offer per share but lowering the minimum net cash condition and extending the tender offer.

Summary

• LAVA Therapeutics N.V. and XOMA Royalty Corporation amended their Share Purchase Agreement on October 17, 2025.
• The cash price per share for tendered shares was reduced to $1.04, down from the original range of $1.16 to $1.24.
• Shareholders will still receive one Contingent Value Right (CVR) per share, with revised terms.
• The CVR now includes a new right to receive up to approximately $0.23 per CVR, dependent on the final determination of certain potential liabilities (Tax Reserve Matter).
• The minimum Closing Net Cash condition for the offer was reduced from $31.5 million to $24.5 million.
• The tender offer expiration was extended from October 17, 2025, to November 12, 2025.
• The Extraordinary General Meeting of Shareholders (EGM) was reconvened for November 7, 2025, to approve transaction-related matters.

Sentiment

Score: 4

Explanation: The significant reduction in the cash offer price per share is a clear negative for shareholders. While the lowered minimum cash condition increases the likelihood of closing and a new CVR component offers potential upside, the immediate and certain value has decreased. The delays also add uncertainty. The overall sentiment is moderately negative due to the reduced cash consideration.

Positives

• The minimum Closing Net Cash condition was reduced from $31.5 million to $24.5 million, increasing the likelihood of the acquisition closing.
• A new component was added to the CVR, offering potential payments of up to approximately $0.23 per CVR based on the resolution of certain potential liabilities, providing an additional avenue for shareholder value.
• The extension of the tender offer and EGM provides additional time for shareholders to consider the revised terms and for the parties to satisfy closing conditions.

Negatives

• The cash amount per share was significantly reduced to $1.04 from the previously agreed range of $1.16 to $1.24, representing a direct decrease in immediate shareholder value.
• The amendment was made due to a 'current understanding of potential liabilities, associated expenses, and the most recent estimates of LAVAs expected cash balance at closing,' indicating unforeseen financial challenges or lower cash reserves.

Risks

• Various closing conditions set forth in the Purchase Agreement and Amendment may not be satisfied or waived, including uncertainties as to the percentage of LAVA's shareholders tendering their shares.
• The possibility that competing offers will be made, potentially disrupting the current transaction.
• The risk that the transactions may not be completed in a timely manner, or at all, which could adversely affect LAVA's business and share price.
• Significant costs associated with the transactions, including potential shareholder or other litigation.
• The risk that activities related to the CVR Agreement, including the new form thereof, may not result in any value to LAVA's shareholders, including payments related to the resolution of certain potential liabilities.
• The possibility that prior to the completion of the transactions, LAVA's or XOMA Royalty's business may experience significant disruptions due to transaction-related uncertainty.
• The announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with employees, manufacturers, suppliers, vendors, or business partners.
• The occurrence of any event, change, or other circumstance that could give rise to the termination of the Purchase Agreement.
• Potential adverse effects on LAVA's business condition and results from general economic and market conditions and overall fluctuations in the United States and international equity markets, including as a result of inflation, heightened interest rates, recent and potential future pandemics and other health crises, and hostilities.

Future Outlook

The proposed acquisition is expected to close in the fourth quarter of 2025, subject to customary closing conditions including a minimum tender of LAVA common shares and shareholder approval at the reconvened EGM. The CVRs offer potential future cash payments based on existing partnerships, disposition of unpartnered programs, and the resolution of a tax reserve matter, but there is no assurance that holders will receive any payments.

Management Comments

• LAVA and XOMA Royalty are entering into the Amendment in light of their current understanding of potential liabilities, associated expenses, and the most recent estimates of LAVAs expected cash balance at closing.

Industry Context

This amendment reflects ongoing adjustments in the biopharmaceutical acquisition landscape, where royalty aggregators like XOMA Royalty seek to expand their portfolios by acquiring companies with promising drug candidates and existing partnerships. The deal highlights the complexities of valuing early-stage biotech assets and the financial adjustments often required as due diligence progresses and liabilities become clearer. LAVA's focus on bispecific gamma delta T cell engagers, with partnerships with major pharmaceutical companies like Pfizer and Johnson & Johnson, positions its assets as attractive for royalty monetization, despite the revised terms.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• **Shareholders**: Will receive a lower cash price per share ($1.04 vs. $1.16-$1.24) but gain a new potential CVR payment component and increased certainty of the deal closing due to a reduced minimum cash condition. The delays in the offer and EGM extend the period of uncertainty.
• **Employees**: The filing mentions that the announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with employees, indicating potential disruption or uncertainty regarding future employment.

Next Steps

• XOMA Royalty will file an amendment to its Tender Offer Statement on Schedule TO with the SEC.
• LAVA will file an amendment to its Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC related to the Offer.
• LAVA will file an amended definitive proxy statement in connection with the reconvened EGM.
• LAVA will send a revised proxy statement and proxy card to each shareholder entitled to vote at the reconvened EGM.
• The Extraordinary General Meeting of Shareholders (EGM) will be held on November 7, 2025, to approve transaction-related matters.
• The tender offer is scheduled to expire on November 12, 2025, unless further extended or terminated.
• The proposed acquisition is expected to close in the fourth quarter of 2025, subject to customary closing conditions.

Key Dates

Recommendation

The reduction in the cash offer price is a negative, but the lowered minimum net cash condition increases the probability of the deal closing. The new CVR component offers speculative upside. Given the increased certainty of the transaction proceeding, but at a lower fixed cash value, a 'hold' recommendation is appropriate for existing shareholders awaiting the completion of the tender offer. New investors should consider the reduced cash component and the speculative nature of the CVRs.

Keywords

LAVA Therapeutics, XOMA Royalty, Acquisition, Tender Offer, Contingent Value Right, CVR, Share Purchase Agreement, Biotechnology, Pharmaceutical, Merger, SEC Filing, LVTX, XOMA